Systemic sclerosis (SSc) has the highest case-specific mortality of any of the auto-immune rheumatic diseases, as well as causing major morbidity. There are emerging data supporting efficacy for some treatment approaches for early patient group together with a growing number of exciting potential novel approaches to treatment that are moving into the clinical arena. This presentation will discuss practical management of early SSc in clinical practice.
Disclosure of Interest D. Khanna Grant/Research support from: Actelion, Astra-Zeneca, Bayer, Biogen-Idec, BMS, DIGNA, Genentech/Roche, Gilead, InterMune, Merck, Takeda, Sanofi-Aventis, Savient, and United Therapeutics, Consultant for: NIH, Scleroderma Foundation, Pulmonary Hypertension Association
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.